<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Launois P</dc:creator>
  <dc:creator>Gumy A</dc:creator>
  <dc:creator>Himmelrich H</dc:creator>
  <dc:creator>Locksley RM</dc:creator>
  <dc:creator>Röcken M</dc:creator>
  <dc:creator>Louis JA</dc:creator>
  <dc:date>2002</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Rapid production of IL-4 by Leishmania homolog of mammalian RACK1 (LACK)-reactive CD4(+) T cells expressing the V beta 4-V alpha 8 TCR chains has been shown to drive aberrant Th2 cell development and susceptibility to Leishmania major in BALB/c mice. In contrast, mice from resistant strains fail to express this early IL-4 response. However, administration of either anti-IL-12 or -IFN-gamma at the initiation of infection allows the expression of this early IL-4 response in resistant mice. In this work we show that Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells also expressing the V beta 4-V alpha 8 TCR chains are the source of the early IL-4 response to L. major in resistant mice given anti-IL-12 or -IFN-gamma Abs only at the onset of infection. Strikingly, these cells were found to be required for the reversal of the natural resistance of C57BL/6 mice following a single administration of anti-IL-12 or -IFN-gamma Abs. Together these results suggest that a deficiency in mechanisms capable of down-regulating the early IL-4 response to L. major contributes to the exquisite susceptibility of BALB/c mice to L. major.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/277858</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.4049/jimmunol.168.9.4628</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/11971011</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Journal of immunology (Baltimore, Md. : 1950). - 2002</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Antibodies</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Antigens, Protozoan</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">CD4-Positive T-Lymphocytes</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Cell Differentiation</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Cells, Cultured</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Cytokines</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Disease Progression</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Interferon-gamma</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Interleukin-12</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Interleukin-4</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Kinetics</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Leishmania major</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Leishmaniasis, Cutaneous</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Mice, Inbred BALB C</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Mice, Inbred C57BL</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Protozoan Proteins</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">RNA, Messenger</dc:subject>
  <dc:subject xmlns:ns21="xml" ns21:lang="en">Receptors, Antigen, T-Cell, alpha-beta</dc:subject>
  <dc:subject xmlns:ns22="xml" ns22:lang="en">Th2 Cells</dc:subject>
  <dc:title xmlns:ns23="xml" ns23:lang="en">Rapid IL-4 production by Leishmania homolog of mammalian RACK1-reactive CD4(+) T cells in resistant mice treated once with anti-IL-12 or -IFN-gamma antibodies at the onset of infection with Leishmania major instructs Th2 cell development, resulting in nonhealing lesions.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
